ReviewJournal of clinical medicine2019
Severe Eosinophilic Asthma.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 116 citations in OpenAlex.
- Trial
- Clinical diagnosis and treatment of eosinophilic asthma by respiratory physicians in China: a cross-sectional survey.Journal of thoracic disease · 2026Article
- Deep learning-based 3D leukocyte differentiation using label-free higher harmonic generation microscopy.Journal of translational medicine · 2026Article
- Multidomain clinical and biological remission with tezepelumab in severe asthma: a 12-month multicentre real-world study.Respiratory research · 2026Observational
- The potential of efferocytosis for the treatment of bronchial asthma: A review of current trends, mechanisms and prospects.Biochemistry and biophysics reports · 2025Review
- The Role of Endobronchial Biopsies in Evaluating Biologic Therapy Response in Severe Asthma.International journal of molecular sciences · 2025Review
- Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR).The World Allergy Organization journal · 2025Article
- Benralizumab and the integrated management of co-morbid severe eosinophilic asthma with chronic rhinosinusitis with nasal polyps.Clinical and translational allergy · 2025Review
- Younger severe asthma patients with interleukin 4 (CC variant) and dupilumab treatment are more likely to achieve clinical remission.BMC pulmonary medicine · 2025Article
- TLR7/8 signaling activation enhances the potency of human pluripotent stem cell-derived eosinophils in cancer immunotherapy for solid tumors.Experimental hematology & oncology · 2025Article
- Proposal of a New Composite Score (DAMADECO) to Simultaneously Evaluate Asthma and CRSwNP Severity in Comorbid Patients.Journal of clinical medicine · 2025Article
- Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: aFrontiers in allergy · 2025Article
- Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma.Frontiers in immunology · 2025Article
- Progesterone modulates the immune microenvironment to suppress ovalbumin-induced airway inflammation by inhibiting NETosis.Scientific reports · 2024Article
- Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study.Journal of clinical medicine · 2024Article
- The Determinants of Eosinophilia in Patients With Severe Asthma.Journal of clinical medicine research · 2024Review
- Moderate-High Blood Eosinophilia Is Associated with Increased Hospitalization and Other Asthma Comorbidities.Biomolecules · 2024Review
- Proteomic signatures of eosinophilic and neutrophilic asthma from serum and sputum.EBioMedicine · 2024Article
- Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.Journal of asthma and allergy · 2024Article
- A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.Journal of managed care & specialty pharmacy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a heterogeneous disease with varying severity. Severe asthma is a subject of constant research because it greatly affects patients' quality of life, and patients with severe asthma experience symptoms, exacerbations, and medication side effects. Eosinophils, although at first considered insignificant, were later specifically associated with features of the ongoing inflammatory process in asthma, particularly in the severe case. In this review, we discuss new insights into the pathogenesis of severe asthma related to eosinophilic inflammation and the pivotal role of cytokines in a spectrum that is usually referred to as "T2-high inflammation" that accounts for almost half of patients with severe asthma. Recent literature is summarized as to the role of eosinophils in asthmatic inflammation, airway remodeling, and airway hypersensitivity. Major advances in the management of severe asthma occurred the past few years due to the new targeted biological therapies. Novel biologics that are already widely used in severe eosinophilic asthma are discussed, focusing on the choice of the right treatment for the right patient. These monoclonal antibodies primarily led to a significant reduction of asthma exacerbations, as well as improvement of lung function and patient quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.